PHARMACYTE BIOTECH, INC. Increase (Decrease) in Other Accounts Payable
PHARMACYTE BIOTECH, INC. (PMCB) reported Increase (Decrease) in Other Accounts Payable of $119.43 thousand for the 3-month period ending 2026-07-31, per its 10-Q filed 2026-09-14.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOtherAccountsPayable · last filed 2026-09-14
- PHARMACYTE BIOTECH, INC. increase (decrease) in other accounts payable for the quarter ending 2026-07-31 was $119.43K, a 80.95% increase year-over-year.
- PHARMACYTE BIOTECH, INC. increase (decrease) in other accounts payable for the quarter ending 2026-04-30 was -$842.56K.
- PHARMACYTE BIOTECH, INC. increase (decrease) in other accounts payable for the quarter ending 2026-01-31 was $178.74K, a 31.09% increase year-over-year.
- PHARMACYTE BIOTECH, INC. increase (decrease) in other accounts payable for the quarter ending 2025-10-31 was $469.71K.
- PHARMACYTE BIOTECH, INC. increase (decrease) in other accounts payable for fiscal 2026 was -$128.10K, a 1402.51% decline from fiscal 2025.
- PHARMACYTE BIOTECH, INC. increase (decrease) in other accounts payable for fiscal 2025 was $9.84K, a 96.23% decline from fiscal 2024.
- PHARMACYTE BIOTECH, INC. increase (decrease) in other accounts payable for fiscal 2024 was $261.09K.
- PHARMACYTE BIOTECH, INC. increase (decrease) in other accounts payable for fiscal 2023 was -$242.95K.
| Period end | Increase (Decrease) in Other Accounts Payable 3 month | Increase (Decrease) in Other Accounts Payable 6 month | Increase (Decrease) in Other Accounts Payable 9 month | Increase (Decrease) in Other Accounts Payable 12 month |
|---|---|---|---|---|
| 2026-07-31 | $119.43K 10-Q · filed 2026-09-14 | -$723.13K derived: sum of 2 quarters · filed 2026-09-14 | -$544.38K derived: sum of 3 quarters · filed 2026-09-14 | -$74.67K derived: sum of 4 quarters · filed 2026-09-14 |
| 2026-04-30 | -$842.56K derived: 10-K 12 month − 10-Q 9 month · filed 2026-07-29 | -$663.82K derived: sum of 2 quarters · filed 2026-07-29 | -$194.11K derived: sum of 3 quarters · filed 2026-07-29 | -$128.10K 10-K · filed 2026-07-29 |
| 2026-01-31 | $178.74K derived: 10-Q 9 month − 10-Q 6 month · filed 2026-03-17 | $648.45K derived: sum of 2 quarters · filed 2026-03-17 | $714.46K 10-Q · filed 2026-03-17 | $628.72K derived: sum of 4 quarters · filed 2026-09-14 |
| 2025-10-31 | $469.71K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-12-18 | $535.72K 10-Q · filed 2025-12-18 | $449.97K derived: sum of 3 quarters · filed 2026-09-14 | $586.33K derived: sum of 4 quarters · filed 2026-09-14 |
| 2025-07-31 | $66.00K 10-Q · filed 2026-09-14 | -$19.74K derived: sum of 2 quarters · filed 2026-09-14 | $116.61K derived: sum of 3 quarters · filed 2026-09-14 | -$88.74K derived: sum of 4 quarters · filed 2026-09-14 |
| 2025-04-30 | -$85.74K derived: 10-K 12 month − 10-Q 9 month · filed 2026-07-29 | $50.61K derived: sum of 2 quarters · filed 2026-07-29 | -$154.75K derived: sum of 3 quarters · filed 2026-07-29 | $9.84K 10-K · filed 2026-07-29 |
| 2025-01-31 | $136.35K derived: 10-Q 9 month − 10-Q 6 month · filed 2026-03-17 | -$69.00K derived: sum of 2 quarters · filed 2026-03-17 | $95.58K 10-Q · filed 2026-03-17 | $750.00 derived: sum of 4 quarters · filed 2026-03-17 |
| 2024-10-31 | -$205.36K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-12-18 | -$40.77K 10-Q · filed 2025-12-18 | -$135.60K derived: sum of 3 quarters · filed 2025-12-18 | $222.43K derived: sum of 4 quarters · filed 2025-12-18 |
| 2024-07-31 | $164.58K 10-Q · filed 2025-09-15 | $69.75K derived: sum of 2 quarters · filed 2025-09-15 | $427.79K derived: sum of 3 quarters · filed 2025-09-15 | -$164.18K derived: sum of 4 quarters · filed 2025-09-15 |
| 2024-04-30 | -$94.83K derived: 10-K 12 month − 10-Q 9 month · filed 2025-08-11 | $263.21K derived: sum of 2 quarters · filed 2025-08-11 | -$328.76K derived: sum of 3 quarters · filed 2025-08-11 | $261.09K 10-K · filed 2025-08-11 |
| 2024-01-31 | $358.04K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-03-17 | -$233.93K derived: sum of 2 quarters · filed 2025-03-17 | $355.92K 10-Q · filed 2025-03-17 | |
| 2023-10-31 | -$591.97K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-12-13 | -$2.12K 10-Q · filed 2024-12-13 | ||
| 2023-07-31 | $589.85K 10-Q · filed 2024-09-17 | |||
| 2023-04-30 | -$242.95K 10-K · filed 2024-08-13 | |||
| 2018-04-30 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2018-07-20 | $0.00 derived: sum of 2 quarters · filed 2018-07-20 | $0.00 derived: sum of 3 quarters · filed 2018-07-20 | $0.00 10-K · filed 2018-07-20 |
| 2018-01-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2018-03-19 | $0.00 derived: sum of 2 quarters · filed 2018-03-19 | $0.00 10-Q · filed 2018-03-19 | $0.00 derived: sum of 4 quarters · filed 2018-07-20 |
| 2017-10-31 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2017-12-14 | $0.00 10-Q · filed 2017-12-14 | $0.00 derived: sum of 3 quarters · filed 2018-07-20 | $0.00 derived: sum of 4 quarters · filed 2018-07-20 |
| 2017-07-31 | $0.00 10-Q · filed 2017-09-13 | $0.00 derived: sum of 2 quarters · filed 2018-07-20 | $0.00 derived: sum of 3 quarters · filed 2018-07-20 | $0.00 derived: sum of 4 quarters · filed 2018-07-20 |
| 2017-04-30 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2018-07-20 | $0.00 derived: sum of 2 quarters · filed 2018-07-20 | $0.00 derived: sum of 3 quarters · filed 2018-07-20 | -$150.00K 10-K · filed 2018-07-20 |
| 2017-01-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2018-03-19 | $0.00 derived: sum of 2 quarters · filed 2018-03-19 | -$150.00K 10-Q · filed 2018-03-19 | -$300.00K derived: sum of 4 quarters · filed 2018-03-19 |
| 2016-10-31 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2017-12-14 | -$150.00K 10-Q · filed 2017-12-14 | -$300.00K derived: sum of 3 quarters · filed 2017-12-14 | -$600.00K derived: sum of 4 quarters · filed 2017-12-14 |
| 2016-07-31 | -$150.00K 10-Q · filed 2017-09-13 | -$300.00K derived: sum of 2 quarters · filed 2017-09-13 | -$600.00K derived: sum of 3 quarters · filed 2017-09-13 | -$700.00K derived: sum of 4 quarters · filed 2017-09-13 |
| 2016-04-30 | -$150.00K derived: 10-K 12 month − 10-Q 9 month · filed 2017-07-27 | -$450.00K derived: sum of 2 quarters · filed 2017-07-27 | -$550.00K derived: sum of 3 quarters · filed 2017-07-27 | -$850.00K 10-K · filed 2017-07-27 |
| 2016-01-31 | -$300.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-03-13 | -$400.00K derived: sum of 2 quarters · filed 2017-03-13 | -$700.00K 10-Q · filed 2017-03-13 | $333.96K derived: sum of 4 quarters · filed 2017-03-13 |
| 2015-10-31 | -$100.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-12-02 | -$400.00K 10-Q · filed 2016-12-02 | $633.96K derived: sum of 3 quarters · filed 2016-12-02 | $600.00K derived: sum of 4 quarters · filed 2016-12-02 |
| 2015-07-31 | -$300.00K 10-Q · filed 2016-09-06 | $733.96K derived: sum of 2 quarters · filed 2016-09-06 | $700.00K derived: sum of 3 quarters · filed 2016-09-06 | $700.00K derived: sum of 4 quarters · filed 2016-09-06 |
| 2015-04-30 | $1.03M derived: 10-K 12 month − 10-Q 9 month · filed 2016-07-29 | $1.00M derived: sum of 2 quarters · filed 2016-07-29 | $1.00M derived: sum of 3 quarters · filed 2016-07-29 | $1.00M 10-K · filed 2016-07-29 |
| 2015-01-31 | -$33.96K derived: 10-Q 9 month − 10-Q/A 6 month · filed 2016-03-08 | -$33.96K derived: sum of 2 quarters · filed 2016-03-08 | -$33.96K 10-Q · filed 2016-03-08 | |
| 2014-10-31 | $0.00 derived: 10-Q/A 6 month − 10-Q/A 3 month · filed 2016-01-19 | $0.00 10-Q/A · filed 2016-01-19 | ||
| 2014-07-31 | $0.00 10-Q/A · filed 2016-01-19 | |||
| 2014-04-30 | $0.00 10-K · filed 2016-07-29 | |||
| 2013-04-30 | $0.00 10-K/A · filed 2016-01-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AIM ImmunoTech Inc. (AIM) | United States | $0.006B | |
| CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) | United States | $0.006B | |
| WINDTREE THERAPEUTICS INC /DE/ (WINT) | United States | $0.003B | -0.32 |
| VivoSim Labs, INC. (VIVS) | United States | $0.003B | |
| Calidi Biotherapeutics, Inc. (CLDI) | United States | $0.003B | |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| CURIS INC (CRIS) | United States | $0.002B | -0.05 |
| Silexion Therapeutics Corp (SLXN) | $0.001B | ||
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |